A recent study involving over 25,000 patients with psoriasis across multiple health care systems worldwide found that patients receiving biologic therapies had a lower risk of developing cardiovascular disease compared to those receiving oral anti-psoriatic medications. The study, spanning from 2014-2025, revealed a 38% relative risk reduction in cardiovascular disease incidence among biologics group. Biologic therapies consistently showed lower cardiovascular risk across various conditions and patient subgroups, with TNF-alpha, IL-17, and IL-23 inhibitors displaying different levels of risk reduction. However, the study noted that its observational design precludes establishing causality.

Source: PLOS Medicine